PERL Clinical Research Study at the Barbara Davis Center

in

The Barbara Davis Center for Diabetes, located at the University of Colorado Anschutz Medical Campus, is actively involved in clinical research. The research division has several on-going studies, as well as ones that are ope​n for enrollment. These studies are all dedicated to the pursuit of preventing diabetes in high-risk patients as well as clinical intervention with those already diagnosed with Type 1 diabetes.

The PERL (Preventing Early Renal Loss in Diabetes) trial is an adult clinical trial to determine whether lowering serum uric acid by means of allopurinol early in the course of kidney disease may be effective in preventing or slowing the decline of renal function in T1D patients. Click here for more information on this promising study.

Inclusion Criteria

    • Diagnosed with type 1 diabetes before age 35
    • T1D for >8 years
    • Ages 18-65
    • History or presence of microalbuminuria
    • Estimated GFR (eGFR) between 45-99.9
    • Serum Uric Acid >4.5 mg/dl

COMIRB number: 13-2457/ approval date: Nov 11, 2013
Principal Investigator: David Maahs
Study Coordinator: Vicky Gage, 303-724-8369​